WEREWOLF THERAPEUTICS, INC.
11.30%
5,481,539
1785530
95075A107
Nov 12, 2025
Nov 17, 2025, 08:00 PM
Reporting Persons (14)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| ANSBERT GADICKE | Individual | 11.30% | 5,481,539 | 0 | 5,481,539 |
| LUKE EVNIN | Individual | 7.20% | 3,515,880 | 0 | 3,515,880 |
| Todd Foley | Individual | 5.40% | 2,617,924 | 0 | 2,617,924 |
| MPM BioVentures 2014 LLC | Other | 5.40% | 2,617,924 | 0 | 2,617,924 |
| MPM BioVentures 2014 GP LLC | Other | 5.20% | 2,536,092 | 0 | 2,536,092 |
| MPM BioVentures 2014, L.P. | Partnership | 4.90% | 2,377,515 | 2,377,515 | 0 |
| MPM BioImpact LLC | Other | 4.00% | 1,965,659 | 0 | 1,965,659 |
| UBS Oncology Impact Fund L.P. | Partnership | 4.00% | 1,965,659 | 1,965,659 | 0 |
| Oncology Impact Fund (Cayman) Management L.P. | Partnership | 4.00% | 1,965,659 | 0 | 1,965,659 |
| MPM ONCOLOGY INNOVATIONS FUND LP | Partnership | 1.10% | 521,485 | 521,485 | 0 |
| MPM Oncology Innovations Fund GP LLC | Other | 1.10% | 521,485 | 0 | 521,485 |
| MPM ASSET MANAGEMENT LLC | Other | 0.80% | 376,471 | 376,471 | 0 |
| MPM BioVentures 2014 (B), L.P. | Partnership | 0.30% | 158,577 | 158,577 | 0 |
| MPM Asset Management Investors BV2014 LLC | Other | 0.20% | 81,832 | 81,832 | 0 |
Disclosure Items (3)
Common Stock
WEREWOLF THERAPEUTICS, INC.
200 TALCOTT AVENUE, WATERTOWN, MA, 02472
See rows (11) and (13) of the Filing Persons Owner Profile of this Amendment No. 2 for the aggregate number of Common Stock and percentages of the shares of Common Stock beneficially owned by the Filing Person. The Common Stock are held as follows: * 2,377,515 shares are held directly by BV 2014; * 158,577 shares are held directly by BV 2014(B); * 81,832 shares are held directly by AM BV2014 LLC; * 521,485 shares are held directly by MPM OIF; * 376,471 share by AMC LLC; and * 1,965,659 shares are held directly by UBS Oncology. BV 2014 GP and BV 2014 LLC are the direct and indirect general partners of BV 2014 and BV 2014(B) and, accordingly, may be deemed to beneficially own the shares held by BV 2014 and BV 2014(B). BV 2014 LLC is the managing member of AM BV2014 LLC and, accordingly, may be deemed to beneficially own the shares held by AM BV2014 LLC. MPM OIF GP is the general Partner of MPM OIFOIF and, accordingly, may be deemed to beneficially own the shares held by MPM OIF. BioImpact and Oncology Cayman are the direct and indirect general partners of UBS Oncology and, accordingly, may be deemed to beneficially own the shares held by UBS Oncology. Drs. Gadicke and Evnin and Mr. Foley are the managing directors of BV 2014 LLC and, accordingly, may be deemed to beneficially own the shares held by BV 2014, BV 2014(B) and AM BV2014 LLC. Drs. Gadicke and Evnin are the members of AM LLC and managers of MPM OIF GP and, accordingly, may be deemed to beneficially own the shares held by AM LLC and MPM OIF. Dr. Gadicke is the managing partner of BioImpact and, accordingly may be deemed to beneficially own the shares held by UBS Oncology. Calculation of the percentage of the shares of Common Stock beneficially owned is based upon 48,540,200 Common Stock outstanding as of October 29, 2025, as reported in the Issuer's Form 10-Q filed with the SEC on November 4, 2025.
See rows (7) through (10) of the Filing Persons Owner Profile of this Amendment No. 2 for the number of shares as to which there is sole power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition.
The Reporting Persons sold the following Common Stock in the open market since the date of filing Amendment No. 1: Date of Price Range Ave. Price Sold by Sold by Sold By AM BV Sold by Sold by Sold by Sale BV 2014 BV 2104(B) 2014 LLC MPM OIF AM BV UBS Oncology 2014 LLC 11/04/25 $1.17-$1.30 $1.22 60,937 4,064 2,098 13,420 9,645 50,324 11/05/25 $1.19-$1.25 $1.22 20,798 1,387 717 4,580 3,292 17,176 11/06/25 $1.185-$1.27 $1.21 23,619 1,575 814 5,201 3,738 19,505 11/07/25 $1.075-$1.188 $1.11 29,704 1,981 1,022 6,541 4,702 24,530 11/10/25 $1.145-$1.21 $1.18 21,067 1,405 725 4,640 3,335 17,398 11/11/25 $1.115-$1.17 $1.14 24,208 1,615 832 5,331 3,832 19,992 11/12/25 $1.065-$1.145 $1.09 17,640 1,177 607 3,885 2,792 14,568 11/13/25 $0.918-$1.07 $0.98 39,450 2,631 1,359 8,688 6,244 32,579 11/14/25 $0.895-$0.9551 $0.93 26,736 1,783 921 5,888 4,232 22,080 11/17/25 $0.9183-$0.99 $0.95 24,750 1,651 851 5,451 3,918 20,440
Inapplicable.
Inapplicable.
Joint Filing Statement